> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-127/
- Published: 2017-03-19T12:00:00.000Z
- Updated: 2026-09-14T22:12:26.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138239

[**Draft Guide on Generic Rifaximin Bioequivalence** ](https://www.fdaweb.com/draft-guide-on-generic-rifaximin-bioequivalence/)03/17/2017  
*Federal Register* notice: FDA makes available a revised draft guidance for industry on generic rifaximin oral tablets and bioequivalence issues.

[**FDA Eliminates Regional Director Positions**](https://www.fdaweb.com/fda-eliminates-regional-director-positions/) 03/17/2017  
*Federal Register* final rule technical amendment: FDA makes revisions to Chapter I of its regulations to eliminate the position of regional food and drug director.

[**Comments Sought on Pharmacogenomic Data Submissions**](https://www.fdaweb.com/comments-sought-on-pharmacogenomic-data-submissions/) 03/17/2017  
*Federal Register* Notice: FDA seeks comments on an information collection extension for its “Guidance for Industry on Pharmacogenomic Data Submissions.”

[**Comments Sought on 510(k) Cover Sheet**](https://www.fdaweb.com/comments-sought-on-510-k-cover-sheet/) 03/17/2017  
*Federal Register* Notice: FDA seeks comments on an information collection reinstatement for “Premarket Notification—21 CFR Part 807, Subpart E. 

[**Comments Sought on Device Pediatric Use Information**](https://www.fdaweb.com/comments-sought-on-device-pediatric-use-information-2/) 03/17/2017  
*Federal Register* Notice: FDA seeks comments on an information collection extension for its guidance on “Providing Information About Pediatric Uses of Medical Devices Under Section 515A of the Federal Food, Drug, and Cosmetic Act.”

[**Cyanocobalamin Not Withdraw Over Safety/Effectiveness**](https://www.fdaweb.com/cyanocobalamin-not-withdraw-over-safety-effectiveness/) 03/16/2017  
*Federal Register* notice: FDA determines that cyanocobalamin injection, 1 milligram per milliliter in a 10 milliliter vial, was not withdrawn for reasons related to safety or effectiveness.

[**Sarcopenia Meeting Location Changed**](https://www.fdaweb.com/sarcopenia-meeting-location-changed/) 03/16/2017  
*Federal Register* notice: FDA corrects a 12/15/2016 notice entitled “Public Meeting on Patient-Focused Drug Development for Sarcopenia” to reflect a change in meeting location.

[**FDA Posts 10 OMB Comment Request Notices**](https://www.fdaweb.com/fda-posts-10-omb-comment-request-notices/) 03/15/2017  
*Federal Register*: FDA posts ten Office of Management and Budget information collection notices that have been backlogged and now released after a regulatory review by the Trump administration.

[**Glucose Monitor Display Put Into Class 2**](https://www.fdaweb.com/glucose-monitor-display-put-into-class-2/) 03/15/2017  
*Federal Register* Final Order: FDA classifies as a Class 2 (special controls) medical device the continuous glucose monitor secondary display.

[**Genomic Sequence Analyzer Put Into Class 2**](https://www.fdaweb.com/genomic-sequence-analyzer-put-into-class-2/) 03/15/2017  
*Federal Register* Final Order: FDA classifies as a Class 2 (special controls) medical device the high throughput genomic sequence analyzer for clinical use.